Omeros CORP 8-K filings

Omeros Corporation announced the appointment of Joseph Schocken to its Board of Directors, effective August 12, 2026, expanding the board to nine members.

Omeros Corporation announced robust second quarter 2026 financial results, highlighted by a significant increase in YARTEMLEA revenue and improved operational cash flow.

Omeros Corporation announced the completion of a $14.5 million repurchase of its 9.50% Convertible Senior Notes due 2029, bringing the total retired to $30.5 million.

Omeros Corporation announced the expected completion of a $16.0 million repurchase of its 9.50% Convertible Senior Notes due 2029 and entered into agreements for an additional repurchase of up to $14.5 million.

Omeros Corporation announced the results of its 2026 Annual Meeting, where shareholders re-elected three directors and approved the company's executive compensation and incentive plans.

Omeros Corporation announced agreements to repurchase up to $16.0 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029.

Omeros Corporation announced first quarter 2026 financial results, highlighting the launch of YARTEMLEA and a significant shift to net income, driven by product sales and a non-cash gain.

Omeros Corporation reports strong Q4 2025 net income driven by the zaltenibart transaction and FDA approval of YARTEMLEA, significantly reducing debt and targeting positive cash flow by 2027.

Omeros Corporation disclosed a preliminary, unaudited cash and short-term investments balance of approximately $171.5 million as of December 31, 2025.

Omeros Corporation announced FDA approval of YARTEMLEA (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Omeros Corporation completed the sale and licensing of its clinical-stage MASP-3 inhibitor, zaltenibart, to Novo Nordisk for an upfront payment of $240 million and up to $1.81 billion in potential milestones and royalties.

Omeros Corporation announced third quarter 2025 financial results, a significant licensing agreement with Novo Nordisk for zaltenibart, and updates on its narsoplimab regulatory review.

Omeros Corporation has entered into an Asset Purchase and License Agreement with Novo Nordisk for exclusive global rights to zaltenibart (OMS906), potentially yielding up to $2.1 billion in payments and royalties.

Omeros Corporation reported a significantly reduced net loss in Q2 2025, driven by lower manufacturing expenses, while its narsoplimab BLA target action date for TA-TMA was extended to December 26, 2025.

Omeros Corporation announced a $22 million registered direct offering with Polar Asset Management Partners, while also disclosing a three-month extension for its narsoplimab BLA PDUFA date and an FDA request for more data on its PDE7 inhibitor program.

Omeros Corporation announced that its shareholders elected two Class I directors, approved the advisory resolution on executive compensation, and ratified Ernst & Young LLP as its independent auditor for fiscal year 2025 at the Annual Meeting held on June 27, 2025.

Omeros Corporation finalizes terms for a new series of 9.50% Convertible Senior Notes due in 2029 through a second supplemental indenture.

Omeros Corporation completes a private exchange of convertible notes, announces an equitization transaction, and reports its first quarter 2025 financial results, highlighting a net loss and strategic prioritization of resources.

The FDA has accepted Omeros' resubmitted Biologics License Application (BLA) for narsoplimab in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), setting a target action date in late September 2025.

Omeros Corporation reports its Q4 and year-end 2024 financial results, highlighted by the resubmission of the narsoplimab BLA to the FDA and progress in its clinical development programs.

Omeros Corporation reports robust survival benefits for narsoplimab in treating TA-TMA patients within an expanded access program, supporting its upcoming BLA resubmission to the FDA.

Omeros Corporation announced positive results from statistical sensitivity analyses confirming the robustness of narsoplimab's survival benefit in patients with transplant-associated thrombotic microangiopathy (TA-TMA).

Omeros Corporation announced that narsoplimab, its monoclonal antibody, showed a significant survival benefit in patients with transplant-associated thrombotic microangiopathy (TA-TMA) compared to an external control group, paving the way for a BLA resubmission.

Omeros Corporation announced its third quarter 2024 financial results, highlighting a reduced net loss compared to the previous year and progress in its clinical development programs.

Omeros Corporation announced a net loss of $56.0 million for the second quarter of 2024, despite progress in clinical programs and a significant debt restructuring.

Omeros Corporation has announced the retirement of its Vice President of Finance, Chief Accounting Officer, and Treasurer, along with the appointment of his successor, and the results of its 2024 Annual Meeting of Shareholders.

Omeros Corporation has significantly strengthened its balance sheet by securing a $92.1 million loan, extending debt maturity to 2028 and repurchasing a substantial portion of its 2026 convertible notes.

Omeros Corporation announced its first quarter 2024 financial results, highlighted by a $115.5 million royalty agreement and progress in its clinical programs.

Omeros Corporation announced its fourth quarter and year-end 2023 financial results, highlighting a reduced net loss in Q4 but an overall net loss for the year, alongside progress in its clinical development programs.

Omeros Corporation has amended its royalty agreement with DRI Healthcare Acquisitions, receiving $115 million upfront in exchange for an expanded interest in OMIDRIA royalties.